West Pharmaceutical Services Inc
WST- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000105770
In the last 90 days, West Pharmaceutical Services Inc insiders filed 0 open-market purchases and 2 sales; 833 institutions reported holding it in 13F filings for Q2 2026, worth $25.3B in total; Gates Foundation Trust is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $5.44M in total
- 2
- 13F holdersQ2 2026, +87 vs. previous quarter
- 833
- 13F valueReported value at the end of Q2 2026
- $25.3B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding WST, Q2 2026
1 superinvestor reports holding West Pharmaceutical Services Inc on Form 13F. Percentages are the stock's share of each portfolio.
Gates Foundation Trust
Bill Gates
0.5%
West Pharmaceutical Services Inc's share of the portfolio
- Shares
- 444,500
- Value
- $159.6M
Latest insider trades
Open-market purchases and sales by West Pharmaceutical Services Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 (view filing)4:37 PM ET | Sep 11-15 | 4 days | Favorite Annette FSr. VP & Chief HR Officer | SSale | −7.52K | $355.03 | −$2.67M | −25.6%21.8K after | 3 lots10b5-1 |
| Sep 10, 2026 (view filing)5:36 PM ET | Sep 8 | 2 days | Favorite Annette FSr. VP & Chief HR Officer | SSale | −8.13K | $340.81 | −$2.77M | −32.6%16.8K after | 3 lots |
| Apr 29, 2026 (view filing) | Apr 27 | 2 days | Favorite Annette FSr. VP & Chief HR Officer | SSale | −2.82K | $305.20 | −$859.7K | −14.3%16.8K after | |
| Apr 29, 2026 (view filing) | Apr 27 | 2 days | Winters ChadVP, Chief Accounting Officer | SSale | −896 | $300.67 | −$269.4K | −37.0%1.52K after | |
| Oct 31, 2024 (view filing) | Oct 29 | 2 days | Witherspoon CharlesVP & Treasurer | SSale | −703 | $310.40 | −$218.2K | −35.9%1.25K after | 2 lots |
| Aug 21, 2024 (view filing) | Aug 19 | 2 days | Witherspoon CharlesVP & Treasurer | SSale | −1.03K | $300.00 | −$308.7K | −41.0%1.48K after | 2 lots |
| Aug 21, 2024 (view filing) | May 10 | 103 daysLate | Hofmann Thomas WDirector | SSale | −617 | $365.92 | −$225.8K | −1.4%43.6K after | |
| Aug 8, 2024 (view filing) | Aug 6 | 2 days | Green Eric MarkPresident, CEO and Board Chair | SSale | −30.7K | $304.71 | −$9.36M | −16.0%161.9K after | 10b5-1 |
| Aug 8, 2024 (view filing) | May 7 | 93 days | Green Eric MarkPresident, CEO and Board Chair | SSale | −66.0K | $366.65 | −$24.2M | −30.1%152.9K after | Amended3 lots10b5-1 |
| Jun 13, 2024 (view filing) | Jun 12 | 1 day | Abraham SiljiSVP, Chief Technology Officer | SSale | −1.80K | $330.78 | −$595.4K | −38.6%2.86K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in West Pharmaceutical Services Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 6,651,784 | $2.39B | 0.04% | −184,930−2.7% | Reduced |
| Vanguard Capital Management LLC | 4,613,134 | $1.66B | 0.04% | −70,152−1.5% | Reduced |
| Vanguard Portfolio Management LLC | 4,015,766 | $1.44B | 0.06% | −78,243−1.9% | Reduced |
| FMR LLC | 3,574,816 | $1.28B | 0.06% | +2,325,068+186.0% | Added |
| State Street Corp | 3,348,698 | $1.20B | 0.04% | +54,920+1.7% | Added |
| Artisan Partners Limited Partnership | 2,411,792 | $865.8M | 1.41% | −246,101−9.3% | Reduced |
| Bank of New York Mellon Corp | 2,043,823 | $733.7M | 0.12% | −422,035−17.1% | Reduced |
| Generation Investment Management LLP | 2,028,322 | $728.2M | 7.08% | −215,654−9.6% | Reduced |
| Geode Capital Management, LLC | 1,903,279 | $680.6M | 0.04% | −9,176−0.5% | Reduced |
| T. Rowe Price Investment Management, Inc. | 1,805,019 | $648.0M | 0.42% | −535,384−22.9% | Reduced |